Synaptogenix Inc (SNPX)

[kld2]

Okay, guys, not bashing here; just my MO: to be skeptical.

I am sure most of you have gone over the Phase 2a results. Nine patients; 6 on Bryostatin, 3 on placebo. No safety or toxicity issues.

A few things called my attention:

1) Patients treated had mild dementia

2) In March 17, 2015 press release it states: "An additional secondary objective of the study was the evaluation of efficacy following a single dose of bryostatin. As expected with a single dose of bryostatin, there was no measurable improvement in cognition in this mildly impaired patient population."

3) Current Ph2b trial treats moderately severe to severe patients.

Is nobody concerned about the fact that, other than 3 Compassionate Study patients, Bryostatin has demonstrated no signs of efficacy? In fact, they state in the above-mentioned pr that there was no measurable improvement, at least in mild patients.

Interesting to consider how Bryostatin does not apparently improve patients with mild Azheimer's but might improve patients with severe Alzheimer's. That's what Neurotrope is betting on anyway.

Anyone like to take a jab at why Neurotrope thinks Bryostatin might improve cognition in severe patients but not mild patients?